Adenocarcinoma

Summary

Adenocarcinoma (MONDO:0004970) is a disease (an umbrella term covering 64 Mondo subtypes) with 2 cohort genes and 211 clinical trials. Top therapeutic interventions include carboplatin, crizotinib, and lapatinib.

At a glance

• Umbrella term: 64 Mondo subtypes
• Cohort genes: 2
• ClinVar variants: 2
• Clinical trials: 211

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adenocarcinoma
Mondo ID	MONDO:0004970
EFO	EFO:0000228
MeSH	D000230
DOID	DOID:299
NCIT	C2852
SNOMED CT	443961001
UMLS	C0001418
MedGen	122
Is cancer (heuristic)	no

Also known as: adenocarcinoma · adenocarcinoma NOS (morphologic abnormality) · adenocarcinoma, malignant · adenocarcinoma, no subtype (morphologic abnormality) · adenocarcinomas · ADNOS

Data availability: 2 ClinVar variants · 1 cell line.

Disease family

An umbrella term covering 64 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma

Related subtypes (48): retroperitoneum carcinoma, head and neck carcinoma, peritoneal carcinoma, neuroendocrine carcinoma, laryngeal carcinoma, bone carcinoma, carcinoma ex pleomorphic adenoma, scrotal carcinoma, skin carcinoma, malignant myoepithelioma, trachea carcinoma, epithelial-myoepithelial carcinoma, lipid-rich carcinoma, comedocarcinoma, in situ carcinoma, urinary bladder carcinoma, breast carcinoma, squamous cell carcinoma, lung carcinoma, prostate carcinoma, renal carcinoma, uterine carcinoma, vulvar carcinoma, large cell carcinoma, undifferentiated carcinoma, basaloid carcinoma, cribriform carcinoma, digestive system carcinoma, fallopian tube carcinoma, penile carcinoma, sarcomatoid carcinoma, thymic carcinoma, transitional cell carcinoma, ureter carcinoma, papillary carcinoma, Krebs 2 carcinoma, thyroid gland carcinoma, vaginal carcinoma, choroid plexus carcinoma, malignant epithelial tumor of ovary, mucin-producing carcinoma, basal cell carcinoma, carcinoma of urethra, combined carcinoid and adenocarcinoma, secondary carcinoma, invasive carcinoma, glycogen-rich carcinoma, lymph node carcinoma

Subtypes (64): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 pathogenic, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
181974	NM_000051.4(ATM):c.6095G>A (p.Arg2032Lys)	ATM	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
12365	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	TP53	Pathogenic	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 28 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma
ATM	Orphanet:100	Ataxia-telangiectasia
ATM	Orphanet:1331	Familial prostate cancer
ATM	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
ATM	Orphanet:227535	Hereditary breast cancer
ATM	Orphanet:370109	Ataxia-telangiectasia variant
ATM	Orphanet:440437	Familial colorectal cancer Type X
ATM	Orphanet:52416	Mantle cell lymphoma
ATM	Orphanet:67038	B-cell chronic lymphocytic leukemia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	clinvar
ATM	HGNC:795	ENSG00000149311	Q13315	Serine-protein kinase ATM	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
ATM	Serine-protein kinase ATM	Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Transcription factor	1	4.1×	0.228

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
ATM	Kinase	yes	2.7.11.1	PI3/4_kinase_cat_dom, PIK-rel_kinase_FAT, FATC_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ganglionic eminence	1
tendon of biceps brachii	1
ventricular zone	1
calcaneal tendon	1
colonic epithelium	1
corpus callosum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
ATM	286	ubiquitous	marker	calcaneal tendon, colonic epithelium, corpus callosum

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
ATM	7,383

Intra-cohort edges

A	B	Sources
ATM	TP53	biogrid_interaction, string_interaction

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
ATM	Q13315	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 95. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
TP53 Regulates Transcription of Caspase Activators and Caspases	2	951.7×	8e-05	TP53, ATM
Stabilization of p53	2	761.3×	8e-05	TP53, ATM
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	2	543.8×	8e-05	TP53, ATM
Regulation of TP53 Activity through Methylation	2	543.8×	8e-05	TP53, ATM
Regulation of TP53 Degradation	2	292.8×	2e-04	TP53, ATM
Autodegradation of the E3 ubiquitin ligase COP1	2	265.6×	2e-04	TP53, ATM
TP53 Regulates Transcription of DNA Repair Genes	2	181.3×	4e-04	TP53, ATM
DNA Damage/Telomere Stress Induced Senescence	2	163.1×	4e-04	TP53, ATM
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	2	146.4×	5e-04	TP53, ATM
G2/M Checkpoints	2	134.3×	5e-04	TP53, ATM
G2/M DNA damage checkpoint	2	120.2×	6e-04	TP53, ATM
Regulation of TP53 Activity through Phosphorylation	2	117.7×	6e-04	TP53, ATM
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	5710.0×	0.001	TP53
Regulation of TP53 Expression	1	2855.0×	0.002	TP53
Transcriptional activation of cell cycle inhibitor p21	1	1427.5×	0.004	TP53
Activation of NOXA and translocation to mitochondria	1	951.7×	0.006	TP53
Sensing of DNA Double Strand Breaks	1	951.7×	0.006	ATM
RUNX3 regulates CDKN1A transcription	1	815.7×	0.006	TP53
PI5P Regulates TP53 Acetylation	1	634.4×	0.008	TP53
Activation of PUMA and translocation to mitochondria	1	571.0×	0.008	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	475.8×	0.008	TP53
Pexophagy	1	475.8×	0.008	ATM
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	475.8×	0.008	ATM
Urea cycle	1	439.2×	0.008	TP53
Regulation of TP53 Activity through Association with Co-factors	1	407.9×	0.008	TP53
Diseases of DNA Double-Strand Break Repair	1	407.9×	0.008	ATM
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	407.9×	0.008	ATM
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	1	380.7×	0.008	TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	356.9×	0.008	TP53
p53-Dependent G1 DNA Damage Response	1	356.9×	0.008	ATM

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
replicative senescence	2	991.3×	2e-04	TP53, ATM
cellular response to gamma radiation	2	601.9×	2e-04	TP53, ATM
determination of adult lifespan	2	432.1×	3e-04	TP53, ATM
somitogenesis	2	374.5×	3e-04	TP53, ATM
DNA damage response, signal transduction by p53 class mediator	2	358.6×	3e-04	TP53, ATM
cellular senescence	2	295.6×	3e-04	TP53, ATM
positive regulation of neuron apoptotic process	2	271.8×	3e-04	TP53, ATM
double-strand break repair	2	203.0×	5e-04	TP53, ATM
neuron apoptotic process	2	185.2×	5e-04	TP53, ATM
multicellular organism growth	2	137.0×	9e-04	TP53, ATM
negative regulation of helicase activity	1	8426.0×	0.001	TP53
cellular response to actinomycin D	1	8426.0×	0.001	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	8426.0×	0.001	TP53
negative regulation of G1 to G0 transition	1	8426.0×	0.001	TP53
regulation of apoptotic process	2	83.4×	0.002	TP53, ATM
positive regulation of mitochondrial membrane permeability	1	4213.0×	0.002	TP53
oligodendrocyte apoptotic process	1	4213.0×	0.002	TP53
establishment of RNA localization to telomere	1	4213.0×	0.002	ATM
establishment of protein-containing complex localization to telomere	1	4213.0×	0.002	ATM
negative regulation of glucose catabolic process to lactate via pyruvate	1	4213.0×	0.002	TP53
positive regulation of telomerase catalytic core complex assembly	1	4213.0×	0.002	ATM
negative regulation of pentose-phosphate shunt	1	4213.0×	0.002	TP53
regulation of cell cycle	2	74.6×	0.002	TP53, ATM
protein stabilization	2	66.9×	0.002	TP53, ATM
pre-B cell allelic exclusion	1	2808.7×	0.002	ATM
obsolete homolactic fermentation	1	2808.7×	0.002	TP53
cellular response to nitrosative stress	1	2808.7×	0.002	ATM
signal transduction by p53 class mediator	1	2808.7×	0.002	TP53
negative regulation of miRNA processing	1	2808.7×	0.002	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	2808.7×	0.002	TP53

Therapeutics

Drugs indicated for this disease

6 approved, 17 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Docetaxel Anhydrous	Approved (phase 4)
Fluorouracil	Approved (phase 4)
Mitomycin	Approved (phase 4)
Thiotepa	Approved (phase 4)
Tislelizumab	Approved (phase 4)
Zolbetuximab	Approved (phase 4)
Bevacizumab	Phase 3 (in late-stage trials)
Cadonilimab	Phase 3 (in late-stage trials)
Capecitabine	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Domvanalimab	Phase 3 (in late-stage trials)
Gimeracil	Phase 3 (in late-stage trials)
Nimotuzumab	Phase 3 (in late-stage trials)
Nivolumab	Phase 3 (in late-stage trials)
Oteracil	Phase 3 (in late-stage trials)
Oxaliplatin	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pulocimab	Phase 3 (in late-stage trials)
Rivoceranib	Phase 3 (in late-stage trials)
Sugemalimab	Phase 3 (in late-stage trials)
Tegafur	Phase 3 (in late-stage trials)
Toripalimab	Phase 3 (in late-stage trials)
Zimberelimab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adebrelimab, Albumin Human, Avelumab, Bemarituzumab, Camrelizumab, Capivasertib, Carboplatin, Ceralasertib, Cetuximab, Crizotinib, Degarelix, Durvalumab, Envafolimab, Enzalutamide, Epirubicin, Gemcitabine, Ipilimumab, Irinotecan, KN-026, Lapatinib, Lenvatinib, Metformin, Motexafin Gadolinium, Osimertinib, Palbociclib, Pembrolizumab, Pemetrexed, Ramucirumab, Selumetinib, Serplulimab, Sintilimab, Sitravatinib, Sorafenib, Sunitinib, Trastuzumab, Trastuzumab Deruxtecan.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN
ATM	AMIODARONE HYDROCHLORIDE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
ATM	35	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	ATM, TP53
FURAZOLIDONE	4	ATM, TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	ATM, TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
ATM	240	Binding:233, Functional:5, ADMET:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ATM	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869
ATM	240

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	ATM, TP53
FURAZOLIDONE	4	ATM, TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	ATM, TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	TP53, ATM
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 211.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	68
Not specified	66
PHASE1	33
PHASE1/PHASE2	17
PHASE3	15
PHASE4	8
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01579721	PHASE4	COMPLETED	Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
NCT01665417	PHASE4	UNKNOWN	Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
NCT02103257	PHASE4	UNKNOWN	Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
NCT02151149	PHASE4	COMPLETED	Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02194556	PHASE4	UNKNOWN	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
NCT02335151	PHASE4	COMPLETED	CTC Pancreatic Adenocarcinoma
NCT04401059	PHASE4	UNKNOWN	Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
NCT05581121	PHASE3	RECRUITING	PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT07385703	PHASE3	NOT_YET_RECRUITING	Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT00127478	PHASE2/PHASE3	COMPLETED	A Long Term Safety Study With Atrasentan
NCT00140075	PHASE3	COMPLETED	Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT00443196	PHASE2/PHASE3	COMPLETED	Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
NCT00548548	PHASE3	COMPLETED	A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
NCT00917384	PHASE3	COMPLETED	Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
NCT00949650	PHASE3	COMPLETED	BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
NCT01009593	PHASE3	TERMINATED	Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01121393	PHASE3	COMPLETED	BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
NCT01130233	PHASE3	UNKNOWN	Randomized Trial on Robotic Assisted Resection for Rectal Cancer
NCT01249352	PHASE2/PHASE3	COMPLETED	A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
NCT01363466	PHASE3	TERMINATED	Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
NCT01365156	PHASE3	COMPLETED	Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
NCT02125240	PHASE3	UNKNOWN	Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
NCT03013010	PHASE3	COMPLETED	PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
NCT04222972	PHASE3	TERMINATED	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05325164	PHASE3	WITHDRAWN	Methadone for ‘Adenocarcinopathic’ Pain Treatment
NCT02133196	PHASE2	RECRUITING	T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
NCT03488667	PHASE2	ACTIVE_NOT_RECRUITING	Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
NCT04069273	PHASE2	RECRUITING	Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04543071	PHASE2	RECRUITING	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT04605913	PHASE1/PHASE2	RECRUITING	Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
NCT05101356	PHASE1/PHASE2	RECRUITING	A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
NCT05776524	PHASE2	RECRUITING	Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT05922930	PHASE1/PHASE2	RECRUITING	Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT06121700	PHASE2	RECRUITING	Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06241469	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
NCT07259317	PHASE2	RECRUITING	Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07368985	PHASE2	NOT_YET_RECRUITING	Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
NCT07574541	PHASE2	NOT_YET_RECRUITING	Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
NCT00054873	PHASE2	COMPLETED	Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	9
CRIZOTINIB	4	3
LAPATINIB	4	3
RAMUCIRUMAB	4	3
AFATINIB	4	2
PEMETREXED	4	2
PRALSETINIB	4	2
AVELUMAB	4	1
AXITINIB	4	1
CAPECITABINE	4	1
CAPIVASERTIB	4	1
DESFLURANE	4	1
ERIBULIN MESYLATE	4	1
ERLOTINIB	4	1
GEMCITABINE	4	1
INTERFERON ALFA-2A	4	1
IPILIMUMAB	4	1
IXABEPILONE	4	1
METHADONE	4	1
OSIMERTINIB	4	1
PALBOCICLIB	4	1
PANITUMUMAB	4	1
PARICALCITOL	4	1
SELUMETINIB	4	1
SORAFENIB	4	1
SUNITINIB	4	1
TEMSIROLIMUS	4	1
TISLELIZUMAB	4	1
TRAMETINIB	4	1
ICOTINIB	3	3